ClinicalTrials.gov record
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
ClinicalTrials.gov ID: NCT00042068
Public ClinicalTrials.gov record NCT00042068. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis
Study identification
- NCT ID
- NCT00042068
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
Interventions
- Meloxicam Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2002
- Primary completion
- Not listed
- Completion
- Jun 30, 2003
- Last update posted
- Oct 31, 2013
2002 – 2003
United States locations
- U.S. sites
- 72
- U.S. states
- 29
- U.S. cities
- 65
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Suites 570 (research) & 600 (PI) | Huntsville | Alabama | 35801 | — |
| Suite 200 | Montgomery | Alabama | 36106 | — |
| Suite 140 | Anchorage | Alaska | 99508 | — |
| #106 | Glendale | Arizona | 85308 | — |
| Suite 601 | Phoenix | Arizona | 85012 | — |
| Suite 201 | Phoenix | Arizona | 85015 | — |
| Boehringer Ingelheim Investigational Site | Los Angeles | California | 90048 | — |
| Boehringer Ingelheim Investigational Site | Pasadena | California | 91105 | — |
| Suite 100 | Rancho Cucamonga | California | 91730 | — |
| Boehringer Ingelheim Investigational Site | Rancho Mirage | California | 92270-4469 | — |
| Suite 208 | San Diego | California | 92108 | — |
| Suite 202 | San Diego | California | 92120 | — |
| Suite 301 | San Leandro | California | 94578 | — |
| Suite A | Santa Maria | California | 93454 | — |
| Westlake Medical Research | Westlake Village | California | 91361 | — |
| Suite 200 | Colorado Springs | Colorado | 80910 | — |
| Suites 205 & 206 | Danbury | Connecticut | 06810 | — |
| Suite 300 | Washington D.C. | District of Columbia | 20006 | — |
| Boehringer Ingelheim Investigational Site | Delray Beach | Florida | 33484 | — |
| Boehringer Ingelheim Investigational Site | Gainsville | Florida | 32607 | — |
| Boehringer Ingelheim Investigational Site | Jacksonville | Florida | 32204 | — |
| Boehringer Ingelheim Investigational Site | Largo | Florida | 33773 | — |
| Suite 202 | Miami | Florida | 33173 | — |
| Boehringer Ingelheim Investigational Site | Ocala | Florida | 03474 | — |
| Renstar Medical Research | Ocala | Florida | 34471 | — |
| Boehringer Ingelheim Investigational Site | Orlando | Florida | 32804 | — |
| Suite 2 | Orlando | Florida | 32806 | — |
| Suite 406 | Safety Harbor | Florida | 34695 | — |
| Boehringer Ingelheim Investigational Site | Sarasota | Florida | 34239 | — |
| Boehringer Ingelheim Investigational Site | South Miami | Florida | 33143 | — |
| Suite 101 | St. Petersburg | Florida | 33710 | — |
| Radiant Research | Stuart | Florida | 34996 | — |
| Suite 203 | Tampa | Florida | 33614 | — |
| Boehringer Ingelheim Investigational Site | Zephyrhills | Florida | 33540 | — |
| Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | 83814-2644 | — |
| Suite 202 | Idaho Falls | Idaho | 83404 | — |
| Boehringer Ingelheim Investigational Site | Lake Forest | Illinois | 60045 | — |
| Boehringer Ingelheim Investigational Site | Rockford | Illinois | 61103 | — |
| Boehringer Ingelheim Investigational Site | Springfield | Illinois | 62704 | — |
| Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | 46202 | — |
| Attn: Kathy Stoddard, Director | Wichita | Kansas | 67207 | — |
| Suite 306 | Wheaton | Maryland | 20902 | — |
| Truesdale Clinic | Fall River | Massachusetts | 02720 | — |
| Suite 202 | Kalamazoo | Michigan | 49009 | — |
| Suite 101 | St Louis | Missouri | 63128 | — |
| Suite 240 | St Louis | Missouri | 63141 | — |
| Boehringer Ingelheim Investigational Site | Lincoln | Nebraska | 68506 | — |
| Boehringer Ingelheim Investigational Site | Reno | Nevada | 89502-1196 | — |
| PC, Jackson Commons D-2 | Medford | New Jersey | 08055 | — |
| Suite 8 | Mercerville | New Jersey | 08619 | — |
| Boehringer Ingelheim Investigational Site | New York | New York | 10021 | — |
| Suite 100 | Charlotte | North Carolina | 28210 | — |
| Boehringer Ingelheim Investigational Site | Columbus | Ohio | 43214 | — |
| Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | 74135 | — |
| Boehringer Ingelheim Investigational Site | Camp Hill | Pennsylvania | 17011 | — |
| Altoona Center for Clinical Research | Duncansville | Pennsylvania | 16635 | — |
| Boehringer Ingelheim Investigational Site | Erie | Pennsylvania | 16508-1256 | — |
| Suite D | Mechanicsburg | Pennsylvania | 17055 | — |
| Suite 331-333 | Johnston | Rhode Island | 02919 | — |
| Boehringer Ingelheim Investigational Site | Columbia | South Carolina | 29204 | — |
| Suite H | North Charleston | South Carolina | 29406 | — |
| Boehringer Ingelheim Investigational Site | Orangeburg | South Carolina | 29118 | — |
| Boehringer Ingelheim Investigational Site | Austin | Texas | 78705 | — |
| Boehringer Ingelheim Investigational Site | Dallas | Texas | 75225 | — |
| Radiant Research | Dallas | Texas | 75231 | — |
| Suite 200 | Dallas | Texas | 75246-1632 | — |
| Suite 500 | Lubbock | Texas | 79410 | — |
| Suites 207 | San Antonio | Texas | 78217 | — |
| Suite 2A | Falls Church | Virginia | 22044 | — |
| Boehringer Ingelheim Investigational Site | Everett | Washington | 98201 | — |
| Suite D-3 | Seattle | Washington | 98166-2967 | — |
| Boehringer Ingelheim Investigational Site | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00042068, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2013 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00042068 live on ClinicalTrials.gov.